LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Emergent BioSolutions Inc

Closed

SectorHealthcare

6.34 -1.86

Overview

Share price change

24h

Current

Min

6.28

Max

6.35

Key metrics

By Trading Economics

Income

99M

68M

Sales

33M

222M

EPS

0.71

Profit margin

30.603

Employees

900

EBITDA

120M

133M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+108.98% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

30M

347M

Previous open

8.2

Previous close

6.34

Technical Score

By Trading Central

Confidence

Bullish Evidence

Emergent BioSolutions Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 maj 2025, 10:30 UTC

Top News

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 maj 2025, 06:30 UTC

Earnings

5 Things We've Learned From Retail Earnings -- Barrons.com

31 maj 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 maj 2025, 21:30 UTC

Top News

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 maj 2025, 21:15 UTC

Top News

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 maj 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 maj 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 maj 2025, 20:24 UTC

Top News

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 maj 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30 maj 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 maj 2025, 19:29 UTC

Earnings
Acquisitions, Mergers, Takeovers

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 maj 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 maj 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 maj 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 maj 2025, 18:37 UTC

Market Talk
Earnings

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 maj 2025, 18:04 UTC

Top News

S&P 500 Falls After More Trump-China Friction -- WSJ

30 maj 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 maj 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 maj 2025, 17:40 UTC

Acquisitions, Mergers, Takeovers

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 maj 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 maj 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 maj 2025, 17:14 UTC

Top News

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 maj 2025, 16:31 UTC

Earnings

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 maj 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30 maj 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 maj 2025, 16:16 UTC

Top News

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 maj 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 16:14 UTC

Top News

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Peer Comparison

Price change

Emergent BioSolutions Inc Forecast

Price Target

By TipRanks

108.98% upside

12 Months Forecast

Average 13.5 USD  108.98%

High 15 USD

Low 12 USD

Based on 2 Wall Street analysts offering 12 month price targets forEmergent BioSolutions Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.95 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.